Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial
A legfontosabb adatok
- Ki végzi
- Emory University
- Hol
- Atlanta (Egyesült Államok)Mind a 4 helyszín megnézése
- Azonosító
- Állapot
- Leállítva
- Fázis
- 3. fázis
- Résztvevők
- 5 fő vett részt
- Kezdés
- 2024. márc. 8.
- Befejezés
- 2024. jún. 24.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Cetirizine
- Famotidine
- Cetirizine Placebo
- Famotidine Placebo
- A regiszteradat frissítve
- 2025. július 17.
- Miért állt le
- Study was terminated due to lack of funding.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 24 feltétel megnézéseKevesebb
Ki vehet részt
- Adults ≥18 years of age with a history of a SARS-CoV-2 PCR positive test and/or medical records from a healthcare provider that coincides with the diagnosis of long-COVID
- New or worsened symptoms since the onset of COVID-19 that are persistent at the time of enrollment and have lasted for ≥ 12 weeks (including at least one of the following: fatigue, post-exertional malaise (PEM), headache, brain fog, sleep disturbance, dysautonomia
- Confirmation of negative urine or serum human chorionic gonadotropin (HCG) (pregnancy) test in women of childbearing potential
- Willing to use appropriate contraceptives for female and male subjects for the duration of the study
- Has an address (for mailing of study drug) in the state of Georgia
- Able to swallow capsules
- Has reliable access to a mobile phone, tablet, laptop, or desktop computer capable of connecting to the internet via Wi-Fi or a data plan
- Available lab work (CBC and CMP) after the onset of long COVID symptoms
- Willing and able to comply with scheduled visits, treatment plan, and other study procedures including receiving either intervention or placebo
- Willing to not take any of the study medications while enrolled in the study except for essential needs as prescribed by a healthcare provider
Ki nem vehet részt
- Currently immunocompromised from the following: solid organ transplant, bone marrow transplant (BMT), high dose steroids (>20mg prednisone per day), immune modulators, or chemotherapy
- Currently taking opioid analgesics, undergoing treatment for opioid addiction, or taking any other prohibited concomitant medication
- Known sensitivity or adverse reaction to H1 or H2 receptor antagonists, or medication components
- Currently receiving other therapies to treat COVID-19 or Long COVID symptoms, e.g., convalescent plasma, remdesivir, Paxlovid
- No post-acute COVID-19 symptoms (PASC) symptoms at the time of enrollment or PASC symptoms present <12 weeks at the time of enrollment
- Actively enrolled in another Long COVID/PASC interventional trial or participation in another interventional clinical trial in the last 30 days or planned during the trial period
- Other medical conditions occurring after the onset of COVID-19 that can otherwise account for PASC-type symptoms
- Opioid dependence or withdrawal syndrome
- Unstable medical comorbidities (e.g., decompensated cirrhosis, stage III-IV chronic kidney disease, New York Heart Association (NYHA) class III congestive heart failure), per the patient report, telemedicine physical exam, baseline laboratory values (hematology and extended chemistry panels) and/or medical records
- Inability to provide own informed consent
- Currently Hospitalized
- For women of childbearing potential (WOCBP), currently pregnant or plans to become pregnant during the study period; for males with partners of childbearing potential (OCBP), plans to become pregnant during the study period
- Suspected or confirmed pregnancy or breastfeeding
- Participants already on H1 or H2 receptor antagonists within three (3) months of randomization
Helyszínek itt: Egyesült Államok
- Emory HospitalAtlanta, Egyesült Államok
- Emory University Hospital MidtownAtlanta, Egyesült Államok
- Grady Health SystemAtlanta, Egyesült Államok
- Metro-AtlantaAtlanta, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The primary objective of this study is to assess the feasibility and acceptability of methods and procedures to be employed in a larger scale decentralized platform adaptive randomized clinical trial in patients with a history of a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Polymerase Chain Reaction (PCR) positive test and/or medical records from a healthcare provider that coincides with the diagnosis of long-COVID.
A vizsgálat 2 csoportja
- HRA Treatment ArmA vizsgált kezelés
Participants randomized to Treatment Arm will receive dual histamine receptor antagonists: famotidine and cetirizine daily.
Kezelés: Cetirizine és Famotidine
- Placebo ArmPlacebo, összehasonlításként
The compounding study pharmacy will provide placebo capsules to the patients randomized to Placebo. These capsules are manufactured to match each treatment drug for oral administration.
Kezelés: Cetirizine Placebo és Famotidine Placebo
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Feasibility Assessment of a Decentralized Platform Adaptive Double-Blind, Randomized Controlled Trial Investigating Repurposed Drugs in the Treatment of Post-Acute Sequelae of Coronavirus-19 (PASC)
- A regiszteradat frissítve
- 2025. július 17.